Oral News and Research

RSS

Emotionally mature students may experience more positive benefits from sex

New university students might be thinking about exploring another rite of passage when they get to campus: the joy of sex. However, depending on their level of maturity, some students may find less joy than others.

19 Dec 2009

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

Due to a lack of suitable studies, it remains unclear whether children and adolescents with type 1 diabetes benefit more or less from long-term treatment with rapid-acting insulin analogues than with short-acting human insulin.

19 Dec 2009

NSHAP study sheds new light on health and intimate relationships of older people

Researchers and the general public have a new resource for information on the health and intimate relationships of older people, thanks to a newsupplemental issue of The Journals of Gerontology Series B: Psychological and Social Sciences (Volume 64B, Supplement 1).

19 Dec 2009

Oral health care critical for pregnant women and infants

Most pregnant women in America don't see their dentists for important oral health care nearly as often as recommended, which can cause ongoing health problems for both mother and her baby.

19 Dec 2009

Understanding the differences between skull bone and bones in limbs could prevent osteoporosis

Scientists at Queen Mary, University of London have uncovered fundamental differences between the bone which makes up the skull and the bones in our limbs, which they believe could hold the key to tackling bone weakness and fractures.

19 Dec 2009

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Doctors and researchers from the John Theurer Cancer Center at Hackensack University Medical Center recently presented research updates and clinical trial results of more than 20 innovative studies at the American Society of Hematology (ASH) annual meeting from December 5-8, 2009.

18 Dec 2009

Roundup of health policy research and analyses

Urban Institute/Robert Wood Johnson Foundation: What Would Health Care Reform Mean for Small Employers and Their Workers? - "Small employers and their workers face a broad assortment of barriers to obtaining health insurance coverage today," such as "high administrative costs, limited ability to spread health care risk, and a low-wage workforce."

18 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

The TACKLE CANCER FOUNDATION wants to call attention to important news for patients with the blood cancer multiple myeloma. A new study shows patients benefit from daily medical treatments to keep their cancer in check after they have had a stem cell (bone marrow) transplant. The current standard of care is to give patients the transplant and then hold off on additional treatment until they relapse. The new study shows continuous treatment with the oral drug REVLIMID following the transplant significantly prolongs remission, increasing time to disease progression.

18 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Many states still lack the 21st century technology capacity needed for disease surveillance

Today, CDC's Morbidity and Mortality Weekly Report (MMWR) released a report showing that the number of state-level epidemiologists has decreased steadily since 2004, with a marked decline of over 10% since 2006.

18 Dec 2009

Pico-Tesla commences enrollment in its Magneceutical therapy study for type 2 diabetes

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has enrolled the first seven patients for a randomized, double-blind, placebo-controlled Pilot Study of persons who have type 2 diabetes, the most common form of diabetes. The Pilot Study seeks to determine whether the application of magnetic fields generated by the Company’s patented Resonator™ system can be effective as an adjunctive therapy to oral medications in reducing hemoglobin A1c levels.

18 Dec 2009

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

ARIAD Pharmaceuticals, Inc. today announced the completion of patient enrollment in its pivotal, Phase 3 clinical trial of oral ridaforolimus, its investigational mTOR inhibitor, in patients with metastatic soft-tissue and bone sarcomas.

18 Dec 2009

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

Amarillo Biosciences, Inc. (ABI) today announced that its ongoing study of oral interferon as prevention/treatment of influenza and other respiratory illnesses in Perth, Australia is nearing completion.

17 Dec 2009

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint was achieved in the Company’s Phase 2 pain study assessing the efficacy and safety of BEMA Buprenorphine. The positive results follow BDSI’s March 2009 announcement of favorable Phase 1 study results.

17 Dec 2009

LA dentist offers special service packages for Christmas season

To celebrate Christmas and the holiday season, Los Angeles dentist Dr. Neda Naim is thanking new patients for scheduling appointments by providing specials on selected services throughout December.

17 Dec 2009

New application developed by AIM increases health plan staff productivity

A new application developed by American Imaging Management® (AIM) to manage the clinical review of specialty pharmaceuticals has increased health plan staff productivity and the number of drugs reviewed while reducing costs.

17 Dec 2009

FDA Advisory Committee votes against the approval of Tarceva

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 12 to one recommending against approval of the daily pill Tarceva® (erlotinib) for first-line maintenance use in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has not progressed (grown or spread) following first-line treatment with platinum-based chemotherapy.

17 Dec 2009

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the initiation, by its partner Keryx Biopharmaceuticals Inc. ("Keryx") ( KERX), of a Phase 3 registration clinical trial for perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor, in relapsed/refractory multiple myeloma patients.

16 Dec 2009

Opinions: HIV prevention; PEPFAR; H1N1 vaccine donation; developing country R&D; climate change

"For nearly 30 years scientists have been trying to break the back of the AIDS epidemic," but the recent microbicide gel study and an AIDS vaccine trial in Thailand "show just how difficult and how distant that goal is," according to a Washington Post editorial. "While scientists continue searching for a vaccine or a cure, prevention remains paramount," the Washington Post concludes (12/16).

16 Dec 2009

Oral News and Research

Emotionally mature students may experience more positive benefits from sex

Children with type 1 diabetes benefit from rapid-acting insulin analogues; potential harm remains unclear

NSHAP study sheds new light on health and intimate relationships of older people

Oral health care critical for pregnant women and infants

Understanding the differences between skull bone and bones in limbs could prevent osteoporosis

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Roundup of health policy research and analyses

GSK receives European CHMP positive opinion for Revolade

Tackle Cancer Foundation calls attention to REVLIMID for myeloma patients

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Many states still lack the 21st century technology capacity needed for disease surveillance

Pico-Tesla commences enrollment in its Magneceutical therapy study for type 2 diabetes

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

LA dentist offers special service packages for Christmas season

New application developed by AIM increases health plan staff productivity

FDA Advisory Committee votes against the approval of Tarceva

Phase 3 registration clinical trial for perifosine initiated by Keryx Biopharmaceuticals

Opinions: HIV prevention; PEPFAR; H1N1 vaccine donation; developing country R&D; climate change

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News